Literature DB >> 19464933

Does topical wound oxygen (TWO2) offer an improved outcome over conventional compression dressings (CCD) in the management of refractory venous ulcers (RVU)? A parallel observational comparative study.

W Tawfick1, S Sultan.   

Abstract

OBJECTIVES: Topical wound oxygen (TWO(2)) may help wound healing in the management of refractory venous ulcers (RVU). The aim of this study was to measure the effect of TWO(2) on wound healing using the primary end-point of the proportion of ulcers healed at 12 weeks. Secondary end-points were time to full healing, percentage of reduction in ulcer size, pain reduction, recurrence rates and Quality-Adjusted Time Spent Without Symptoms of disease and Toxicity of Treatment (Q-TWiST).
DESIGN: A parallel observational comparative study.
METHODS: Patients with CEAP C(6,s) RVU, assessed by duplex ultrasonography, were managed with either TWO(2) (n=46) or conventional compression dressings (CCD) (n=37) for 12 weeks or till full healing. Patients were followed up at 3 monthly intervals.
RESULTS: At 12 weeks, 80% of TWO(2) managed ulcers were completely healed, compared to 35% of CCD ulcers (p<0.0001). Median time to full healing was 45 days in TWO(2) patients and 182 days in CCD patients (p<0.0001). The pain score threshold in TWO(2) managed patients improved from 8 to 3 by 13 days. After 12-month follow-up, 5 of the 13 healed CCD ulcers showed signs of recurrence compared to none of the 37 TWO(2) healed ulcers. TWO(2) patients experienced a significantly improved Q-TWiST.
CONCLUSION: TWO(2) reduces recurrence rates, alleviates pain and improves the Q-TWiST. We believe it is a valuable tool in the armamentarium of management of RVU.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19464933     DOI: 10.1016/j.ejvs.2009.03.027

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  8 in total

Review 1.  Evidence-based practice standards for the use of topical pressurised oxygen therapy.

Authors:  Heather L Orsted; Randy Poulson; Joseph Baum; Dawn Christensen; Marc Despatis; Kyle Goettl; David Haligowski; Chester Ho; Keith Louis; Deirdre O'Sullivan-Drombolis; Valerie Winberg; Kevin Y Woo
Journal:  Int Wound J       Date:  2012-04-11       Impact factor: 3.315

Review 2.  Topical oxygen therapy & micro/nanobubbles: a new modality for tissue oxygen delivery.

Authors:  Lohrasb R Sayadi; Derek A Banyard; Mary E Ziegler; Zaidal Obagi; Jordyne Prussak; Michael J Klopfer; Gregory Rd Evans; Alan D Widgerow
Journal:  Int Wound J       Date:  2018-01-05       Impact factor: 3.315

3.  New Technique of Applying Topical Oxygen Therapy as a Cost-Effective Procedure.

Authors:  Vivek Agarwal; Shashank Aroor; Nikhil Gupta; Arun Gupta; Nitin Agarwal; Navneet Kaur
Journal:  Indian J Surg       Date:  2015-03-24       Impact factor: 0.656

4.  Effective use of negative pressure wound therapy provides quick wound-bed preparation and complete graft take in the management of chronic venous ulcers.

Authors:  Onur Egemen; Ozay Ozkaya; Muhammed Besir Ozturk; Tolga Aksan; Çağdaş Orman; Mithat Akan
Journal:  Int Wound J       Date:  2011-10-12       Impact factor: 3.315

5.  [Topical hemoglobin promotes wound healing of patients with venous leg ulcers].

Authors:  M Arenbergerova; P Engels; S Gkalpakiotis; Z Dubská; P Arenberger
Journal:  Hautarzt       Date:  2013-03       Impact factor: 0.751

6.  A Retrospective Chart Review of Chronic Wound Patients Treated with Topical Oxygen Therapy.

Authors:  Karen Copeland; Angie R Purvis
Journal:  Adv Wound Care (New Rochelle)       Date:  2017-05-01       Impact factor: 4.730

Review 7.  Challenges in the Treatment of Chronic Wounds.

Authors:  Robert G Frykberg; Jaminelli Banks
Journal:  Adv Wound Care (New Rochelle)       Date:  2015-09-01       Impact factor: 4.730

8.  Transdermal Wound Oxygen Therapy on Pressure Ulcer Healing: A Single-Blind Multi-Center Randomized Controlled Trial.

Authors:  Jalil Azimian; Nahid Dehghan Nayeri; Enis Pourkhaleghi; Monireh Ansari
Journal:  Iran Red Crescent Med J       Date:  2015-11-03       Impact factor: 0.611

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.